Actelion Provides Update on Bosentan in Japan

Japanese Drug Evaluation Committee Favorably Reviews Tracleer for Pulmonary Arterial Hypertension



 -- Formal approval expected in early April 
 -- Market introduction foreseen for spring 2005

ALLSCHWIL, Switzerland, Feb. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced that is has received written confirmation that the drug evaluation committee of the Japanese Health Authority (MHLW) issued a favorable review of bosentan (Tracleer(r)) for the indication Pulmonary Arterial Hypertension following their 25 February 2005 meeting.

This favorable review is forming the basis on which the Japanese government will issue the formal marketing authorization for Tracleer(r) in the coming weeks. Actelion expects that it could commercially introduce Tracleer(r) in Japan in spring 2005.

About Tracleer(r) in Pulmonary Arterial Hypertension (PAH)

Tracleer(r), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Australia, Canada, Switzerland, Israel, Hong Kong, Malaysia, Singapore and Brazil as well as several other smaller territories worldwide. In Japan, Actelion filed for marketing approval of Tracleer(r) in spring 2003.

In clinical trials leading to the marketing approval of the drug, approximately 11% of PAH patients receiving Tracleer(r) experienced abnormal but reversible liver enzyme elevations. It is therefore important that patients undergo monthly liver monitoring. Due to the risk of birth defects, women who are pregnant, or of childbearing age who do not use a reliable method of contraception, must not take Tracleer(r).

About Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United States are afflicted with either primary or secondary forms of the disease related to conditions or tissue disorders that affect the lungs, such as scleroderma, lupus, HIV/AIDS or congenital heart disease.

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarter in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(r), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(r) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union as well as Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact: Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil



            

Coordonnées